This drug promoted by Didier Raoult may soon no longer be administered in France, or to severely ill patients or in clinical trials, after two notices. Clap en
This drug promoted by Didier Raoult may soon no longer be administered in France, or to severely ill patients or in clinical trials, after two notices.
Clap end for the hydroxychloroquine ? This medication, promoted by the controversial Professor Didier Raoult, may soon no longer be administered in France against the Covid-19, or critically ill patients or in clinical trials, after two notices published at one time this Tuesday.
READ ALSO >> Didier Raoult : “The politicians are all holograms”
In the first opinion, very expected, the High public health council (HCSP), seized by the ministry of Health, recommends “not to use hydroxychloroquine alone or in conjunction with a macrolide (one family of antibiotics) in the treatment of Covid-19”. It also recommends to “evaluate the benefit/risk of the use of hydroxychloroquine in the treatment trials”, and “to strengthen the national regulatory and international of different trials evaluating hydroxychloroquine in the Covid-19”.
Your support is essential. Subscribe for $ 1 support Us
to reach these conclusions, the HCSP has analyzed “publications on the subject,” as well as “reports of the regional centres of pharmacovigilance about potentially serious side effects, particularly cardiovascular, in connection with the use of this medicine”. He concluded “in the absence of clinical study to be sufficiently robust demonstrating the efficacy of hydroxychloroquine in the Covid-19 regardless of the severity of the infection.”
Sixteen trials authorised in France to evaluate its effectiveness
For its part, the Agency of the drug (MSNA) announced that it had “launched (…) a procedure for the suspension of the inclusions of patients in clinical trials in France” on the hydroxychloroquine, which means that it will not be possible to add new patients in the trials already in progress. This suspension will take effect after a period of 24 hours of a contradictory procedure with the organizers of these trials.
READ ALSO >> Didier Raoult : “in The beginning, I had doubts about the chloroquine, but more now”
Sixteen trials have been authorised in France to evaluate the efficacy of hydroxychloroquine in the treatment of Covid-19. “The patients under treatment with hydroxychloroquine in the context of these clinical trials will be able to continue until the end of the protocol, does, however, the MSNA.
These opinions following the publication of a study pointing out the inefficiencies and risks of using this medication for the sick of the coronavirus. The publication of this study in the prestigious medical journal The Lancet has already prompted the WHO (world health Organization) to suspend Monday the clinical trials it conducts with hydroxychloroquine in several countries as a precaution.
the study of The “Lancet” is “lousy” for Didier Raoult
In France, outside of clinical trials, the use of hydroxychloroquine against the Covid-19 is allowed in the hospital only and only for serious cases on collegial decision making of doctors. Saturday, in the light of the study in the Lancet, the minister of Health Olivier Veran had entered the HCSP he proposes a “revision of the overriding rules of limitation” fixed by a decree.
READ ALSO >> Covid-19 and hydroxychloroquine : a study points to an increased risk of death
Derivative of chloroquine (malaria drug), hydroxychloroquine, is prescribed to combat autoimmune diseases, lupus, or rheumatoid arthritis. It is part of the numerous treatments tested since the beginning of the outbreak of coronavirus, but its use in this indication is the subject of fierce controversy.
Read our complete file
Covid-19 : hydroxychloroquine
Hydroxychloroquine and Covid : a look back on a runaway toxic VIDEO. Didier Raoult : the great maintenance very cash Didier Raoult : “The politicians are all holograms”
one of its main proponents is professor Didier Raoult, of the university hospital Institute (IHU) Méditerranée Infection in Marseille, who uses it in patients with mild forms, in association with an antibiotic of the macrolide, azithromycin. In a video uploaded on Monday, Didier Raoult found that the study in the Lancet was “lousy” and rejected its conclusions.
Date Of Update: 26 May 2020, 14:58
Categories: Optical Illusion
Source: newstars.edu.vn